Pages that link to "Q38028654"
Jump to navigation
Jump to search
The following pages link to GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins (Q38028654):
Displaying 21 items.
- N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins (Q26771611) (← links)
- Chemical and Structural Analysis of an Antibody Folding Intermediate Trapped during Glycan Biosynthesis (Q27673777) (← links)
- Strategies and challenges for the next generation of therapeutic antibodies (Q34111699) (← links)
- ADME of biologics-what have we learned from small molecules? (Q36065589) (← links)
- Revisiting the role of glycosylation in the structure of human IgG Fc. (Q36252642) (← links)
- Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs (Q37547107) (← links)
- A review of advanced small‐scale parallel bioreactor technology for accelerated process development: Current state and future need (Q37839908) (← links)
- Nanoengineered glycan sensors enabling native glycoprofiling for medicinal applications: towards profiling glycoproteins without labeling or liberation steps (Q38032457) (← links)
- Non-conventional expression systems for the production of vaccine proteins and immunotherapeutic molecules (Q39025466) (← links)
- Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies (Q41177029) (← links)
- Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry (Q41718653) (← links)
- Marketing approval of mogamulizumab: a triumph for glyco-engineering (Q42333453) (← links)
- Biosimilar, biobetter and next generation therapeutic antibodies (Q42732007) (← links)
- 6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland (Q42732008) (← links)
- 5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland (Q42869354) (← links)
- Rapid and multi-level characterization of trastuzumab using sheathless capillary electrophoresis-tandem mass spectrometry. (Q42906654) (← links)
- Inactivation of a GAL4-like transcription factor improves cell fitness and product yield in glycoengineered Pichia pastoris strains (Q43074457) (← links)
- One-pot N-glycosylation remodeling of IgG with non-natural sialylglycopeptides enables glycosite-specific and dual-payload antibody-drug conjugates (Q48987144) (← links)
- Glycoengineering of antibody (Herceptin) through yeast expression and in vitro enzymatic glycosylation (Q50133462) (← links)
- 9th annual European Antibody Congress, November 11-13, 2013, Geneva, Switzerland (Q51238255) (← links)
- Homogeneous production and characterization of recombinant N-GlcNAc-protein in Pichia pastoris (Q92605184) (← links)